Investing Profile

Jill carroll

Photo of Jill carroll, Principal at SR One

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Duke University Network
SR One Principal
CompanyStageDateRound SizeTotal Raised
Odyssey Therapeutics
Series BOct 2022$170M
Series ADec 2021$220M
Co-investors: Elena Viboch (General Catalyst), Carl Gordon (OrbiMed)
HotSpot Therapeutics
Series CNov 2021$100M
Series BMay 2020$65M
Co-investors: Graziano Seghezzi (Soffinova Partners), Bruce Booth (Atlas Venture), Ash Khanna (Pivotal bioVenture Partners)
Tioma Therapeutics
Series AAug 2016$86M
Co-investors: Peter Moldt (Novo Ventures), John McKearn (RiverVest), Carole Nuechterlein (Roche Venture Fund)
Series BNov 2012$38M
Principal S.R. One Ltd2011 - Present
VP, Corporate Development Limerick Biopharma2010 - 2011
Sr Director, Strategic Planning & Corporate Development Dynavax Technologies2004 - 2010
Director, Market Analysis Clearview Projects2001 - 2004
Consultant Mercer Management Consulting1999 - 2001
Johns Hopkins University MS Biochemistry
Duke University BS Chemistry